{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:17:55Z","timestamp":1793315875555,"version":"4.5.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Burkitt lymphoma (BL) is a highly aggressive, B-cell, non-Hodgkin lymphoma categorized into endemic, sporadic, and immunodeficiency-associated subtypes. BL has distinct pathologic and clinical features, characterized by rapidly progressive tumors with high rates of extranodal involvement. Next-generation-sequencing analyses have further characterized the genomic landscape of BL and our understanding of disease pathogenesis, although these findings have yet to influence treatment. Although most patients are cured with intensive combination chemotherapy, given the paucity of randomized trials, optimal therapy has not been defined. Furthermore, treatment of elderly patients, patients with central nervous system involvement, or those with relapsed disease remains an unmet need. In this review, we highlight the clinical, pathologic, and genomic features, as well as standard and emerging treatment options for adult patients with BL.<\/jats:p>","DOI":"10.1182\/blood.2019004099","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T17:58:06Z","timestamp":1605031086000},"page":"743-750","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":102,"title":["The treatment of Burkitt lymphoma in adults"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-5129","authenticated-orcid":false,"given":"Jennifer","family":"Crombie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":false,"given":"Ann","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"197","key":"2021021116225282900_B1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/bjs.18004619704","article-title":"A sarcoma involving the jaws in African children","volume":"46","author":"Burkitt","year":"1958","journal-title":"Br J Surg"},{"issue":"2","key":"2021021116225282900_B2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/1097-0142(196103\/04)14:2<258::AID-CNCR2820140206>3.0.CO;2-7","article-title":"Malignant lymphoma in African children. I. A clinical syndrome","volume":"14","author":"Burkitt","year":"1961","journal-title":"Cancer"},{"issue":"20","key":"2021021116225282900_B3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2021021116225282900_B4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood-2018-04-844472","article-title":"How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa","volume":"132","author":"Gopal","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2021021116225282900_B5","first-page":"812","article-title":"Management of adults with Burkitt lymphoma","volume":"16","author":"Gastwirt","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"issue":"6","key":"2021021116225282900_B6","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1073\/pnas.0608745104","article-title":"Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9","volume":"104","author":"Parroche","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9822","key":"2021021116225282900_B7","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","article-title":"Burkitt\u2019s lymphoma","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet"},{"key":"2021021116225282900_B8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fonc.2019.00109","article-title":"Epstein Barr Virus associated B-cell lymphomas and iatrogenic lymphoproliferative disorders","volume":"9","author":"Crombie","year":"2019","journal-title":"Front Oncol"},{"issue":"6","key":"2021021116225282900_B9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2021021116225282900_B10","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1080\/10428194.2020.1747068","article-title":"Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy","volume":"61","author":"Zayac","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2021021116225282900_B11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/PAS.0000000000000332","article-title":"Epstein-Barr virus (EBV)-positive sporadic burkitt lymphoma: an age-related lymphoproliferative disorder?","volume":"39","author":"Satou","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"2021021116225282900_B12","first-page":"blood.2020006926","article-title":"Burkitt lymphoma in the modern era: real world outcomes and prognostication across 30 US cancer centers [published online ahead of print 14 July 2020]","author":"Evens","year":"2020","journal-title":"Blood"},{"issue":"25","key":"2021021116225282900_B13","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-03-275917","article-title":"AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and\/or biology?","volume":"116","author":"Guech-Ongey","year":"2010","journal-title":"Blood"},{"issue":"17","key":"2021021116225282900_B14","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1002\/cncr.30112","article-title":"Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: analysis of the National Cancer Data Base","volume":"122","author":"Olszewski","year":"2016","journal-title":"Cancer"},{"issue":"11","key":"2021021116225282900_B15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1200\/JOP.18.00148","article-title":"Approach to the diagnosis and treatment of adult Burkitt\u2019s lymphoma","volume":"14","author":"Dunleavy","year":"2018","journal-title":"J Oncol Pract"},{"issue":"1","key":"2021021116225282900_B16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1309\/AJCP93LJPTRQPDKR","article-title":"Immunophenotypic variations of Burkitt lymphoma","volume":"134","author":"Kelemen","year":"2010","journal-title":"Am J Clin Pathol"},{"issue":"19","key":"2021021116225282900_B17","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1182\/blood-2014-06-538504","article-title":"How I treat Burkitt lymphoma in adults","volume":"124","author":"Jacobson","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2021021116225282900_B18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ijc.2910170108","article-title":"Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas","volume":"17","author":"Zech","year":"1976","journal-title":"Int J Cancer"},{"issue":"24","key":"2021021116225282900_B19","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1073\/pnas.79.24.7837","article-title":"Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells","volume":"79","author":"Taub","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2021021116225282900_B20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/ni.2428","article-title":"The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry","volume":"13","author":"Dominguez-Sola","year":"2012","journal-title":"Nat Immunol"},{"issue":"1","key":"2021021116225282900_B21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","article-title":"c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells","volume":"151","author":"Nie","year":"2012","journal-title":"Cell"},{"issue":"2","key":"2021021116225282900_B22","doi-asserted-by":"crossref","first-page":"a014282","DOI":"10.1101\/cshperspect.a014282","article-title":"Oncogenic mechanisms in Burkitt lymphoma","volume":"4","author":"Schmitz","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"23","key":"2021021116225282900_B23","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt\u2019s lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"issue":"23","key":"2021021116225282900_B24","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt\u2019s lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2021021116225282900_B25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat Genet"},{"issue":"7418","key":"2021021116225282900_B26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"issue":"12","key":"2021021116225282900_B27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"issue":"22","key":"2021021116225282900_B28","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"issue":"19","key":"2021021116225282900_B29","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/blood.2019001880","article-title":"The whole-genome landscape of Burkitt lymphoma subtypes","volume":"134","author":"Panea","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2021021116225282900_B30","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","article-title":"Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma","volume":"133","author":"Grande","year":"2019","journal-title":"Blood"},{"issue":"19","key":"2021021116225282900_B31","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"2021021116225282900_B32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br J Haematol"},{"issue":"24","key":"2021021116225282900_B33","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1182\/blood-2012-12-475558","article-title":"Trends in survival of patients with Burkitt lymphoma\/leukemia in the USA: an analysis of 3691 cases","volume":"121","author":"Costa","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2021021116225282900_B34","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1002\/cncr.28264","article-title":"Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Castillo","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"2021021116225282900_B35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1586\/14737140.2014.866042","article-title":"Improving the accuracy in prognosis for Burkitt lymphoma patients","volume":"14","author":"Castillo","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"2021021116225282900_B36","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/1097-0142(1967)20:5<756::AID-CNCR2820200530>3.0.CO;2-P","article-title":"Long-term remissions following one and two-dose chemotherapy for African lymphoma","volume":"20","author":"Burkitt","year":"1967","journal-title":"Cancer"},{"issue":"12","key":"2021021116225282900_B37","first-page":"2578","article-title":"Long-term survival of patients with Burkitt\u2019s lymphoma: an assessment of treatment and other factors which may relate to survival","volume":"27","author":"Clifford","year":"1967","journal-title":"Cancer Res"},{"issue":"7","key":"2021021116225282900_B38","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdh262","article-title":"Treatment of Burkitt\u2019s\/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens","volume":"15","author":"Smeland","year":"2004","journal-title":"Ann Oncol"},{"issue":"3","key":"2021021116225282900_B39","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"issue":"8","key":"2021021116225282900_B40","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 study [published correction appears in Ann Oncol. 2002;13(12):1961]","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol"},{"issue":"6","key":"2021021116225282900_B41","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2021021116225282900_B42","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt\u2019s-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021021116225282900_B43","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.20143","article-title":"Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251","volume":"100","author":"Rizzieri","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"2021021116225282900_B44","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.12736","article-title":"Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B Study 10002","volume":"165","author":"Rizzieri","year":"2014","journal-title":"Br J Haematol"},{"issue":"12","key":"2021021116225282900_B45","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","article-title":"Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol","volume":"16","author":"Divin\u00e9","year":"2005","journal-title":"Ann Oncol"},{"issue":"20","key":"2021021116225282900_B46","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt\u2019s lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"22","key":"2021021116225282900_B47","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021021116225282900_B48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-017-3167-7","article-title":"Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens","volume":"97","author":"Oosten","year":"2018","journal-title":"Ann Hematol"},{"issue":"8","key":"2021021116225282900_B49","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt\u2019s lymphoma: a retrospective analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"issue":"7","key":"2021021116225282900_B50","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"10036","key":"2021021116225282900_B51","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"2021021116225282900_B52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.blre.2006.02.001","article-title":"CNS prophylaxis in lymphoma: who to target and what therapy to use","volume":"20","author":"Hill","year":"2006","journal-title":"Blood Rev"},{"issue":"6","key":"2021021116225282900_B53","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.leu.2403733","article-title":"Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma","volume":"19","author":"van Imhoff","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"2021021116225282900_B54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbmt.2012.11.016","article-title":"Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research","volume":"19","author":"Maramattom","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2021021116225282900_B55","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.24720","article-title":"Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia\/lymphoma","volume":"92","author":"Short","year":"2017","journal-title":"Am J Hematol"},{"issue":"14","key":"2021021116225282900_B56","first-page":"1124","article-title":"Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy","volume":"135","author":"Woessmann","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2021021116225282900_B57","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41409-018-0235-0","article-title":"CAR T cells induce a complete response in refractory Burkitt lymphoma","volume":"53","author":"Avigdor","year":"2018","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/6\/743\/1799971\/bloodbld2019004099c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/6\/743\/1799971\/bloodbld2019004099c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T16:05:24Z","timestamp":1613145924000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/6\/743\/474125\/The-treatment-of-Burkitt-lymphoma-in-adults"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019004099","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]}}}